Market Overview

UPDATE: Stifel Initiates Coverage on Argos Therapeutics on Positive Outlook

Related ARGS
10 Stocks That Plummeted The Past Three Days On Increasing Volume
15 Stocks Which Rallied Four Days, Then Sold Off Yesterday

In a report published Tuesday, Stifel analyst Joel Sendek initiated coverage on Argos Therapeutics (NASDAQ: ARGS) with a Buy rating and $16.00 price target.

In the report, Stifel noted, “We are initiating coverage of Argos Therapeutics, Inc with a Buy rating and a $16 price target. We base our price target on our expectation for positive overall survival data in 1H16 leading to 2017 approval and ultimately $653M in 2021 worldwide sales in renal cell carcinoma (RCC).

"We see the Phase II results of AGS-003 as encouraging as it implies both a survival advantage for AGS-003 as well as biomarker data that validates the underlying approach of their immune-cell based therapies. While the Phase II results from RCC were uncontrolled, the 30.2 month overall survival is more than double the 14.7 month historical overall survival in a similar patient population.”

Argos Therapeutics closed on Monday at $11.00.

Latest Ratings for ARGS

Apr 2016Roth CapitalMaintainsBuy
Apr 2016Roth CapitalMaintainsBuy
Mar 2016JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for ARGS
View the Latest Analyst Ratings

Posted-In: Joel Sendek StifelAnalyst Color Initiation Analyst Ratings


Related Articles (ARGS)

View Comments and Join the Discussion!